Dr. Reisner is chair of the scientific advisory board for Cell Source and has equity in the company. These financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.

Called cryoablation, the procedure has not been federally approved for breast cancer treatment, but clinical trials are ...

Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer -- Follows recent Orphan Drug designation in ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

TAMEST (Texas Academy of Medicine, Engineering, Science and Technology) has announced Gerta Hoxhaj, Ph.D., Assistant ...

In 17 heavily pretreated NSCLC EGFR mutant (EGFR mut) patients the combination shows an ORR of 24% and a DCR of 71%; tumor ...

Aucatzyl is a chimeric antigen receptor (CAR) T-cell therapy, a type of therapy that uses genetic modification to train the ...

INSEMA and SOUND are among four trials designed to evaluate omission of SLNB in patients with clinically node-negative early ...